Lacosamide Genepharm

Lacosamide, the active ingredient in Lacosamide Genepharm, is an anticonvulsant presented as an oral formulation for oral use. It treats partial‑onset seizures and epilepsy in patients requiring seizure control.

GNH USA supplies Lacosamide Genepharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of seizure disorders, particularly focal epilepsies.

- Partial‑onset seizures: reduces the frequency of seizures in patients with focal epilepsy. - Focal epilepsy: improves overall seizure control when used as adjunct therapy. - Refractory epilepsy: offers an additional option for patients whose seizures are not controlled by first‑line agents.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Headache: recurrent or persistent head pain. - Fatigue: increased tiredness or lack of energy.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm, especially PR‑interval prolongation. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Elevated liver enzymes: indicating possible hepatic stress.

Before initiating therapy, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver function tests regularly. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Pregnancy: risk unknown; use only if potential benefit justifies the potential risk. - Concomitant antiepileptics: monitor for additive CNS depression. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide efficacy. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive effectiveness. - Alcohol: may enhance CNS depression. - Antidepressants (e.g., SSRIs): monitor for increased dizziness or sedation. - Antihypertensives: observe for potential blood pressure changes.